Trevena Completes $35M Series B Financing

Trevena, Inc., a King of Prussia, Pennsylvania-based pharmaceutical company focused on discovering and developing G-protein coupled receptor (GPCR) biased ligands, has completed a $35m Series B financing.
The round was led by existing investors Polaris Venture Partners and New Enterprise Associates, with participation from all other existing investors Alta Partners, Healthcare Ventures and Yasuda Enterprise Development Company.
The capital infusion will enable Trevena to complete a Phase 2 study of its lead molecule, TRV120027, an angiotensin II type I receptor (AT1R) beta-arrestin biased ligand for treatment of acute heart failure, and to continue advancing its portfolio of GPCR biased ligands.

Join the discussion